Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

Abstract Background Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK) pathway with the MEK inhibitor, trametinib (Tra) have been limited...

Full description

Bibliographic Details
Main Authors: Priya Sriskandarajah, Alexis De Haven Brandon, Kenneth MacLeod, Neil O. Carragher, Vladimir Kirkin, Martin Kaiser, Steven R. Whittaker
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cancer
Subjects:
Multiple myeloma
Trametinib
Dexamethasone
Apoptosis
RAS
Online Access:http://link.springer.com/article/10.1186/s12885-020-06735-2

Internet

http://link.springer.com/article/10.1186/s12885-020-06735-2

Similar Items